1. Home
  2. PODD vs DGX Comparison

PODD vs DGX Comparison

Compare PODD & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • DGX
  • Stock Information
  • Founded
  • PODD 2000
  • DGX 1967
  • Country
  • PODD United States
  • DGX United States
  • Employees
  • PODD N/A
  • DGX N/A
  • Industry
  • PODD Medical/Dental Instruments
  • DGX Medical Specialities
  • Sector
  • PODD Health Care
  • DGX Health Care
  • Exchange
  • PODD Nasdaq
  • DGX Nasdaq
  • Market Cap
  • PODD 16.5B
  • DGX 17.5B
  • IPO Year
  • PODD 2007
  • DGX 1996
  • Fundamental
  • Price
  • PODD $275.81
  • DGX $151.17
  • Analyst Decision
  • PODD Buy
  • DGX Buy
  • Analyst Count
  • PODD 16
  • DGX 14
  • Target Price
  • PODD $271.19
  • DGX $170.93
  • AVG Volume (30 Days)
  • PODD 533.0K
  • DGX 716.2K
  • Earning Date
  • PODD 02-20-2025
  • DGX 01-30-2025
  • Dividend Yield
  • PODD N/A
  • DGX 1.98%
  • EPS Growth
  • PODD 235.68
  • DGX 11.56
  • EPS
  • PODD 5.74
  • DGX 7.44
  • Revenue
  • PODD $1,983,900,000.00
  • DGX $9,539,000,000.00
  • Revenue This Year
  • PODD $23.56
  • DGX $7.33
  • Revenue Next Year
  • PODD $18.07
  • DGX $8.62
  • P/E Ratio
  • PODD $48.09
  • DGX $20.33
  • Revenue Growth
  • PODD 27.42
  • DGX 2.60
  • 52 Week Low
  • PODD $160.19
  • DGX $123.04
  • 52 Week High
  • PODD $279.77
  • DGX $165.32
  • Technical
  • Relative Strength Index (RSI)
  • PODD 61.05
  • DGX 42.75
  • Support Level
  • PODD $260.84
  • DGX $148.70
  • Resistance Level
  • PODD $274.45
  • DGX $154.44
  • Average True Range (ATR)
  • PODD 7.44
  • DGX 2.51
  • MACD
  • PODD 0.65
  • DGX 0.09
  • Stochastic Oscillator
  • PODD 88.34
  • DGX 36.59

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Share on Social Networks: